What Is the Treatment of Central Diabetes Insipidus?
Central diabetes insipidus (CDI) results from AVP deficiency and presents with persistent polyuria and polydipsia. The first-line treatment strategy is pharmacological: replacing AVP activity to abolish symptoms while preventing treatment-induced hyponatremia.
First-Line Treatment
Management centres on pharmacological replacement of AVP using desmopressin (dDAVP), a synthetic hormone analog. Oral formulations are generally preferred, with an intranasal alternative available for patients for whom the oral route is unsuitable.
Dosing schedule, formulation selection, and schedule adjustments differ between partial and complete presentations — see the full structured protocol.
Treatment Goals
- Abolition of polyuria and polydipsia
- Avoidance of hyponatremia secondary to treatment
- Symptomatic relief expected promptly after initiating therapy
References
DOI: 10.1210/clinem/dgac381
- Treatment of CDI depends on the pharmaceutical replacement of AVP with desmopressin, a synthetic analog of the hormone, modified to prolong half-life and diminish vasoconstrictor effects (at the V1 receptor).
- Oral dDAVP is preferred to nasal spray by most patients due to the ease of administration and the continued efficacy when nasal congestion occurs due to coryzal infection.
- Oral preparations include both standard tablets and sublingual preparations "desmotabs melt," both of which are in common use.
- The intranasal formulation of dDAVP was the earliest treatment for chronic CDI.
- Abolition of symptoms of polyuria and polydipsia.
- Avoidance of hyponatremia secondary to treatment.
- Symptomatic relief occurs almost immediately after starting dDAVP, with effective long-term control of polyuria.
View source ↗